Cargando…

Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome

Protein degradation is a fundamental process in all living organisms. An important part of this system is a multisubunit, barrel-shaped protease complex called the proteasome. This enzyme is directly responsible for the proteolysis of ubiquitin- or pup-tagged proteins to smaller peptides. In this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Rožman, Kaja, Alexander, Evan M., Ogorevc, Eva, Bozovičar, Krištof, Sosič, Izidor, Aldrich, Courtney C., Gobec, Stanislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144120/
https://www.ncbi.nlm.nih.gov/pubmed/32178473
http://dx.doi.org/10.3390/molecules25061305
Descripción
Sumario:Protein degradation is a fundamental process in all living organisms. An important part of this system is a multisubunit, barrel-shaped protease complex called the proteasome. This enzyme is directly responsible for the proteolysis of ubiquitin- or pup-tagged proteins to smaller peptides. In this study, we present a series of 92 psoralen derivatives, of which 15 displayed inhibitory potency against the Mycobacterium tuberculosis proteasome in low micromolar concentrations. The best inhibitors, i.e., 8, 11, 13 and 15, exhibited a mixed type of inhibition and overall good inhibitory potency in biochemical assays. N-(cyanomethyl)acetamide 8 (K(i) = 5.6 µM) and carboxaldehyde-based derivative 15 (K(i) = 14.9 µM) were shown to be reversible inhibitors of the enzyme. On the other hand, pyrrolidine-2,5-dione esters 11 and 13 irreversibly inhibited the enzyme with K(i) values of 4.2 µM and 1.1 µM, respectively. In addition, we showed that an established immunoproteasome inhibitor, PR-957, is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (K(i) = 5.2 ± 1.9 µM, k(inact)/K(i) = 96 ± 41 M(−1)·s(−1)). These compounds represent interesting hit compounds for further optimization in the development of new drugs for the treatment of tuberculosis.